# SARTORIUS STEDIM BIOTECH

Summary updated: 2026-10-04T14:38:23.069718Z
Canonical: https://finbar.com/research/companies/sartorius-stedim-biotech

## Overview

Sartorius Stedim Biotech is a life-sciences supplier focused on technologies and services for biopharmaceutical development and manufacturing. Its portfolio includes solutions for cell-line development and media, bioreactors, separation and purification, and the storage and transport of biopharmaceutical products, with single-use technologies among its core offerings. [1](https://www.sartorius.com/en/company/about-sartorius-stedim-biotech-sa) [2](https://www.sartorius.com/download/1725892/h1-2025-download-ir-fact-sheet-ssb-en-data.pdf) The company’s stated mission is to help biopharma customers accelerate drug development and improve manufacturing efficiency, supporting the development of better therapies and more affordable medicine. [3](https://www.sartorius.com/en/company/about-sartorius-stedim-biotech-sa/mission)

Sartorius Stedim Biotech operates internationally, with a presence in around 30 countries and more than 50 locations. [4](https://www.sartorius.com/download/1796564/fy-2025-download-urd-ssb-en-data.pdf) For the year ended December 31, 2025, it reported revenue of €2,967.5 million and 10,265 employees. [5](https://app.finbar.com/go?id=T3222458) [6](https://app.finbar.com/go?id=T7123874)
[1](https://www.sartorius.com/en/company/about-sartorius-stedim-biotech-sa)[2](https://www.sartorius.com/download/1725892/h1-2025-download-ir-fact-sheet-ssb-en-data.pdf)[3](https://www.sartorius.com/en/company/about-sartorius-stedim-biotech-sa/mission)[4](https://www.sartorius.com/download/1796564/fy-2025-download-urd-ssb-en-data.pdf)[5](https://app.finbar.com/go?id=T3222458)[6](https://app.finbar.com/go?id=T7123874)[1](https://www.sartorius.com/en/company/about-sartorius-stedim-biotech-sa)[2](https://www.sartorius.com/download/1725892/h1-2025-download-ir-fact-sheet-ssb-en-data.pdf)[3](https://www.sartorius.com/en/company/about-sartorius-stedim-biotech-sa/mission)[4](https://www.sartorius.com/download/1796564/fy-2025-download-urd-ssb-en-data.pdf)

## Products & services

Sartorius Stedim Biotech’s product portfolio supports biologics manufacturing across cell lines, cell-culture media and reagents; bioreactors; separation, purification and concentration; storage and transport; and process-modelling and optimization software. Applications include monoclonal antibodies, vaccines, antibody-drug conjugates, and cell and gene therapies. The company offers integrated process solutions, including scalable single-use technologies and solutions for intensified or continuous production. [7](https://app.finbar.com/go?id=P16983097)[8](https://app.finbar.com/go?id=P42988454)

Examples include the **Biostat STR Generation 3** single-use bioreactor, with working volumes from 12.5 to 2,000 L; **Sartopore Evo** sterilizing-grade PES membrane filters, including a 0.8 μm prefilter/0.2 μm final-filter configuration; **Flexsafe** single-use bags for fluid storage, shipping, filtration and transfer; and **Sartoflow Advanced**, a modular benchtop tangential-flow filtration system for ultrafiltration and diafiltration. [9](https://www.sartorius.com/en/products/fermentation-bioreactors/single-use-bioreactors/biostat-str)[10](https://shop.sartorius.com/ww/p/sartopore-evo/M_Sartopore_Evo)[11](https://www.sartorius.com/en/products/fluid-management/liquid-storage-shipping/flexsafe-liquid-storage-shipping)[12](https://www.sartorius.com/en/products/process-filtration/tangential-flow-filtration/tff-systems/sartoflow-advanced)

Services include process design, plant planning, validation support, bioprocess consulting and engineering, scale-up, process optimization and validation studies for single-use systems and conventional equipment. Sterile single-use products account for “a good three quarters” of sales revenue, with the share varying by product group and region; the cited report does not give a more granular revenue breakdown by individual product or service. [8](https://app.finbar.com/go?id=P42988454)[13](https://www.sartorius.com/en/services/bioprocess-development-engineering)[14](https://www.sartorius.com/en/services/validation-service)[15](https://app.finbar.com/go?id=P107258085)
[7](https://app.finbar.com/go?id=P16983097)[8](https://app.finbar.com/go?id=P42988454)[15](https://app.finbar.com/go?id=P107258085)[9](https://www.sartorius.com/en/products/fermentation-bioreactors/single-use-bioreactors/biostat-str)[10](https://shop.sartorius.com/ww/p/sartopore-evo/M_Sartopore_Evo)[11](https://www.sartorius.com/en/products/fluid-management/liquid-storage-shipping/flexsafe-liquid-storage-shipping)[12](https://www.sartorius.com/en/products/process-filtration/tangential-flow-filtration/tff-systems/sartoflow-advanced)[13](https://www.sartorius.com/en/services/bioprocess-development-engineering)[14](https://www.sartorius.com/en/services/validation-service)

## Geographic presence

In 2025, Sartorius Stedim Biotech generated about 42% of sales in EMEA (€1,241.5 million), 35% in the Americas (€1,053.4 million) and 23% in Asia|Pacific (€672.6 million). North America and Asia are identified as focal areas in its regional growth strategy. [16](https://app.finbar.com/go?id=P12347253)[17](https://app.finbar.com/go?id=P113431209) Country-level sales included €995.7 million in the United States, €255.8 million in Germany, €173.3 million in China, €157.2 million in South Korea and €120.9 million in France. [18](https://app.finbar.com/go?id=T1343065)

At year-end 2025, the company reported 7,131 employees in EMEA, 1,724 in the Americas and 1,410 in APAC. [6](https://app.finbar.com/go?id=T7123874) The parent company is based in Aubagne, France; its listed group entities span several countries, including France, Germany, Belgium, the United Kingdom and Israel. The company identifies a cell-culture-media facility in Beit HaEmek, Israel, and has also reported manufacturing and R&D expansions in Aubagne and Illkirch, France. [19](https://app.finbar.com/go?id=T2586962)[20](https://app.finbar.com/go?id=P28107370)[21](https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-stedim-biotech-expands-production-of-key-components-for-cell-and-gene-therapies-in-france-1747898)[22](https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-stedim-biotech-expands-manufacturing-and-r-d-capacities-for-innovative-bioprocess-solutions-in-france-1698364)
[16](https://app.finbar.com/go?id=P12347253)[17](https://app.finbar.com/go?id=P113431209)[18](https://app.finbar.com/go?id=T1343065)[6](https://app.finbar.com/go?id=T7123874)[19](https://app.finbar.com/go?id=T2586962)[20](https://app.finbar.com/go?id=P28107370)[21](https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-stedim-biotech-expands-production-of-key-components-for-cell-and-gene-therapies-in-france-1747898)[22](https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-stedim-biotech-expands-manufacturing-and-r-d-capacities-for-innovative-bioprocess-solutions-in-france-1698364)

## Business segments

Sartorius Stedim Biotech reports one operating business segment, **Biopharm**, which accounts for 100% of group sales. Its portfolio serves pharmaceutical and biotechnology companies and contract manufacturers, covering cell lines, culture media and reagents, bioreactors, separation and purification technologies, storage and transport solutions, and process-analysis software. In 2025, Biopharm sales were €2,967.5 million. [23](https://app.finbar.com/go?id=P56976948)[24](https://app.finbar.com/go?id=T2016863)[7](https://app.finbar.com/go?id=P16983097)

Geography is disclosed as a sales view rather than a separate operating segment. In 2025, sales were approximately 42% EMEA, 35% Americas, and 23% Asia Pacific. The 2026 first-half report also presents regional sales, but does not identify additional business segments. [16](https://app.finbar.com/go?id=P12347253)[25](https://www.sartorius.com/download/1845890/h1-2026-download-half-year-report-ssb-en-data.pdf)
[23](https://app.finbar.com/go?id=P56976948)[24](https://app.finbar.com/go?id=T2016863)[7](https://app.finbar.com/go?id=P16983097)[16](https://app.finbar.com/go?id=P12347253)[25](https://www.sartorius.com/download/1845890/h1-2026-download-half-year-report-ssb-en-data.pdf)

## Company history

Stedim was founded in Aubagne, France, in 1978 by Bernard Lemaître and Bernard Vallot. In the early 1990s it developed single-use bag systems for biopharmaceutical manufacturing, and in 1994 it became publicly listed on the Paris stock exchange. [26](https://www.sartorius.com/en/company/about-sartorius-stedim-biotech-sa/history)

On June 29, 2007, Stedim merged with Sartorius’s Biotechnology Division to form Sartorius Stedim Biotech, which was listed on Euronext Paris. [27](https://www.sartorius.com/en/company/about-sartorius-ag/history/2007-today) The company subsequently expanded its bioprocess and development capabilities through acquisitions including TAP Biosystems in 2013, BioOutsource and Cellca in 2015, and Umetrics in 2017. [28](https://ir-reports.sartorius.com/fileadmin/images/ir_reference_document_2013_sartorius_stedim_biotech.pdf) [29](https://www.sartorius.com/download/32724/sag-q1-report-2015-e-data.pdf) [30](https://www.sartorius.com/download/38812/ssb-h1-report-2015-e-data.pdf) [31](https://www.sartorius.com/en/company/newsroom/corporate-news/17476-17476)

From 2021 to 2023, acquisitions of CellGenix, Xell, Albumedix and Polyplus broadened its offerings for cell and gene therapies and other advanced biologics. [32](https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-strengthens-product-portfolio-for-cell-and-gene-therapies-by-acquiring-a-majority-stake-in-cellgenix-817522) [33](https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-acquires-cell-culture-specialist-xell-ag-922684) [34](https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-stedim-biotech-completes-acquisition-of-albumedix-1300590) [35](https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-stedim-biotech-completes-acquisition-of-polyplus-1452176) In 2025, the company completed an expansion at its Aubagne site, adding manufacturing, research and development, and logistics capacity. [22](https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-stedim-biotech-expands-manufacturing-and-r-d-capacities-for-innovative-bioprocess-solutions-in-france-1698364)
[26](https://www.sartorius.com/en/company/about-sartorius-stedim-biotech-sa/history)[27](https://www.sartorius.com/en/company/about-sartorius-ag/history/2007-today)[28](https://ir-reports.sartorius.com/fileadmin/images/ir_reference_document_2013_sartorius_stedim_biotech.pdf)[29](https://www.sartorius.com/download/32724/sag-q1-report-2015-e-data.pdf)[30](https://www.sartorius.com/download/38812/ssb-h1-report-2015-e-data.pdf)[31](https://www.sartorius.com/en/company/newsroom/corporate-news/17476-17476)[32](https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-strengthens-product-portfolio-for-cell-and-gene-therapies-by-acquiring-a-majority-stake-in-cellgenix-817522)[33](https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-acquires-cell-culture-specialist-xell-ag-922684)[34](https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-stedim-biotech-completes-acquisition-of-albumedix-1300590)[35](https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-stedim-biotech-completes-acquisition-of-polyplus-1452176)[22](https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-stedim-biotech-expands-manufacturing-and-r-d-capacities-for-innovative-bioprocess-solutions-in-france-1698364)

## Sources

1. [www.sartorius.com](https://www.sartorius.com/en/company/about-sartorius-stedim-biotech-sa)
2. [www.sartorius.com](https://www.sartorius.com/download/1725892/h1-2025-download-ir-fact-sheet-ssb-en-data.pdf)
3. [www.sartorius.com](https://www.sartorius.com/en/company/about-sartorius-stedim-biotech-sa/mission)
4. [www.sartorius.com](https://www.sartorius.com/download/1796564/fy-2025-download-urd-ssb-en-data.pdf)
5. [SARTORIUS STEDIM BIOTECH — Full financial report (2025 Y), p2](https://app.finbar.com/go?id=T3222458)
6. [SARTORIUS STEDIM BIOTECH — Full financial report (2025 Y), p176](https://app.finbar.com/go?id=T7123874)
7. [SARTORIUS STEDIM BIOTECH — Full financial report (2025 Y), p28](https://app.finbar.com/go?id=P16983097)
8. [SARTORIUS STEDIM BIOTECH — Full financial report (2025 Y), p28](https://app.finbar.com/go?id=P42988454)
9. [www.sartorius.com](https://www.sartorius.com/en/products/fermentation-bioreactors/single-use-bioreactors/biostat-str)
10. [shop.sartorius.com](https://shop.sartorius.com/ww/p/sartopore-evo/M_Sartopore_Evo)
11. [www.sartorius.com](https://www.sartorius.com/en/products/fluid-management/liquid-storage-shipping/flexsafe-liquid-storage-shipping)
12. [www.sartorius.com](https://www.sartorius.com/en/products/process-filtration/tangential-flow-filtration/tff-systems/sartoflow-advanced)
13. [www.sartorius.com](https://www.sartorius.com/en/services/bioprocess-development-engineering)
14. [www.sartorius.com](https://www.sartorius.com/en/services/validation-service)
15. [SARTORIUS STEDIM BIOTECH — Full financial report (2025 Y), p28](https://app.finbar.com/go?id=P107258085)
16. [SARTORIUS STEDIM BIOTECH — Full financial report (2025 Y), p36](https://app.finbar.com/go?id=P12347253)
17. [SARTORIUS STEDIM BIOTECH — Full financial report (2025 Y), p32](https://app.finbar.com/go?id=P113431209)
18. [SARTORIUS STEDIM BIOTECH — Full financial report (2025 Y), p279](https://app.finbar.com/go?id=T1343065)
19. [SARTORIUS STEDIM BIOTECH — Full financial report (2025 Y), p282](https://app.finbar.com/go?id=T2586962)
20. [SARTORIUS STEDIM BIOTECH — Full financial report (2025 Y), p54](https://app.finbar.com/go?id=P28107370)
21. [www.sartorius.com](https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-stedim-biotech-expands-production-of-key-components-for-cell-and-gene-therapies-in-france-1747898)
22. [www.sartorius.com](https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-stedim-biotech-expands-manufacturing-and-r-d-capacities-for-innovative-bioprocess-solutions-in-france-1698364)
23. [SARTORIUS STEDIM BIOTECH — Full financial report (2025 Y), p277](https://app.finbar.com/go?id=P56976948)
24. [SARTORIUS STEDIM BIOTECH — Full financial report (2025 Y), p278](https://app.finbar.com/go?id=T2016863)
25. [www.sartorius.com](https://www.sartorius.com/download/1845890/h1-2026-download-half-year-report-ssb-en-data.pdf)
26. [www.sartorius.com](https://www.sartorius.com/en/company/about-sartorius-stedim-biotech-sa/history)
27. [www.sartorius.com](https://www.sartorius.com/en/company/about-sartorius-ag/history/2007-today)
28. [ir-reports.sartorius.com](https://ir-reports.sartorius.com/fileadmin/images/ir_reference_document_2013_sartorius_stedim_biotech.pdf)
29. [www.sartorius.com](https://www.sartorius.com/download/32724/sag-q1-report-2015-e-data.pdf)
30. [www.sartorius.com](https://www.sartorius.com/download/38812/ssb-h1-report-2015-e-data.pdf)
31. [www.sartorius.com](https://www.sartorius.com/en/company/newsroom/corporate-news/17476-17476)
32. [www.sartorius.com](https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-strengthens-product-portfolio-for-cell-and-gene-therapies-by-acquiring-a-majority-stake-in-cellgenix-817522)
33. [www.sartorius.com](https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-acquires-cell-culture-specialist-xell-ag-922684)
34. [www.sartorius.com](https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-stedim-biotech-completes-acquisition-of-albumedix-1300590)
35. [www.sartorius.com](https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-stedim-biotech-completes-acquisition-of-polyplus-1452176)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.